In addition to EGFR, NSCLC patients carrying ALK or ROS1 rearrangement were shown to respond well to a different TKI drug, crizotinib, while BRAF mutated NSCLC patients can be treated with a combination of BRAF inhibitors, dabrafenib and trametinib9–12. Here, ROS1 is linked to non-small cell lung carcinoma.